776 related articles for article (PubMed ID: 3003170)
21. [Cyclic nucleotide phosphodiesterase from wheat sprouts. Purification, properties, effect of systemic fungicides].
Igumenov BL; Etingof RN
Biokhimiia; 1980 Oct; 45(10):1797-803. PubMed ID: 6263360
[TBL] [Abstract][Full Text] [Related]
22. Does the positive inotropic action of a novel cardiotonic agent, MCI-154, involve mechanisms other than cyclic AMP?
Kitada Y; Narimatsu A; Suzuki R; Endoh M; Taira N
J Pharmacol Exp Ther; 1987 Nov; 243(2):639-45. PubMed ID: 2824754
[TBL] [Abstract][Full Text] [Related]
23. Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts.
Yu H; Cai JJ; Lee HC
Mol Pharmacol; 1996 Sep; 50(3):549-55. PubMed ID: 8794893
[TBL] [Abstract][Full Text] [Related]
24. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
[TBL] [Abstract][Full Text] [Related]
25. Resolution of soluble rat cardiac phosphodiesterases by high performance liquid chromatography.
Bode DC; Kanter JR; Brunton LL
Second Messengers Phosphoproteins; 1988-1989; 12(5-6):235-40. PubMed ID: 2856111
[TBL] [Abstract][Full Text] [Related]
26. [Two forms of cyclic nucleotide phosphodiesterase and Ca-dependent protein regulator from rabbit skeletal muscles].
Lazarevich VG; Men'shikov MIu; Tkachuk VA
Biokhimiia; 1979 Oct; 44(10):1842-51. PubMed ID: 228768
[TBL] [Abstract][Full Text] [Related]
27. Cyclic nucleotides and cyclic nucleotide phosphodiesterases in kidneys from rats with experimental diabetes.
Hoskins B; Luong HB
Res Commun Chem Pathol Pharmacol; 1981 Aug; 33(2):381-4. PubMed ID: 6272381
[TBL] [Abstract][Full Text] [Related]
28. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.
Weishaar RE; Burrows SD; Kobylarz DC; Quade MM; Evans DB
Biochem Pharmacol; 1986 Mar; 35(5):787-800. PubMed ID: 3006691
[TBL] [Abstract][Full Text] [Related]
29. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
31. Positive inotropic activity of 5-amino-6-cyano-1,3-dimethyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrim idine-2,4-dione in cardiac muscle from guinea-pig and man. Part 6: Compounds with positive inotropic activity.
Heber D; Heers C; Ravens U
Pharmazie; 1993 Jul; 48(7):537-41. PubMed ID: 7692456
[TBL] [Abstract][Full Text] [Related]
32. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
Rose RJ; Liu H; Palmer D; Maurice DH
Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
[TBL] [Abstract][Full Text] [Related]
33. Stimulation of hamster adipocyte cyclic 3':5'-nucleotide phosphodiesterase activity by ionophore A23187 and calcium.
Nemecek GM
J Cyclic Nucleotide Res; 1978 Aug; 4(4):299-309. PubMed ID: 214467
[TBL] [Abstract][Full Text] [Related]
34. Implication of cyclic AMP in the positive inotropic effects of cyclic GMP-inhibited cyclic AMP phosphodiesterase inhibitors on guinea pig isolated left atria.
Muller B; Lugnier C; Stoclet JC
J Cardiovasc Pharmacol; 1990 Mar; 15(3):444-51. PubMed ID: 1691369
[TBL] [Abstract][Full Text] [Related]
35. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.
Lugnier C; Schini VB
Biochem Pharmacol; 1990 Jan; 39(1):75-84. PubMed ID: 2153383
[TBL] [Abstract][Full Text] [Related]
36. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
Mushlin P; Boerth RC; Wells JN
Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
[No Abstract] [Full Text] [Related]
37. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
38. Characterization of various horse thyroid forms of cyclic-nucleotide phosphodiesterase [proceedings].
Erneux C; Couchie D
Arch Int Physiol Biochim; 1979 May; 87(2):408-10. PubMed ID: 92956
[No Abstract] [Full Text] [Related]
39. Mechanism of inotropic action of xestoquinone, a novel cardiotonic agent isolated from a sea sponge.
Kobayashi M; Nakamura H; Kobayashi J; Ohizumi Y
J Pharmacol Exp Ther; 1991 Apr; 257(1):82-9. PubMed ID: 1850480
[TBL] [Abstract][Full Text] [Related]
40. Regulation of cyclic nucleotide phosphodiesterase activity.
Vaughan M; Danello MA; Manganiello VC; Strewler GJ
Adv Cyclic Nucleotide Res; 1981; 14():263-71. PubMed ID: 6169258
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
